TNGX
Tango Therapeutics, Inc.NASDAQHealthcare$21.63-6.20%ClosedMarket Cap: $2.51B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.81
P/S
37.78
EV/EBITDA
-21.69
DCF Value
$-13.25
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.3%
Operating Margin
-178.4%
Net Margin
-162.9%
ROE
-50.3%
ROA
-25.5%
ROIC
-29.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-41.9M | $-38.7M | $-0.30 | — |
| FY 2025 | $62.4M | 96.3% | $-111.3M | $-101.6M | $-0.87 | — |
| Q3 2025 | $53.8M | 99.0% | $14.1M | $15.9M | $0.14 | — |
| Q2 2025 | $3.2M | 80.4% | $-41.0M | $-38.9M | $-0.35 | — |
| Q1 2025 | $5.4M | 100.0% | $-42.5M | $-39.9M | $-0.36 | — |
| Q4 2024 | $4.1M | 100.0% | $-40.9M | $-37.7M | $-0.34 | — |
| FY 2024 | $42.1M | 100.0% | $-145.6M | $-130.3M | $-1.19 | — |
| Q3 2024 | $11.6M | 100.0% | $-32.9M | $-29.2M | $-0.27 | — |
| Q2 2024 | $19.9M | 100.0% | $-29.6M | $-25.6M | $-0.24 | — |
| Q1 2024 | $6.5M | 100.0% | $-42.3M | $-37.9M | $-0.35 | — |
| Q4 2023 | $5.4M | 100.0% | $-35.0M | $-30.8M | $-0.32 | — |
| FY 2023 | $36.5M | 100.0% | $-114.2M | $-101.7M | $-1.08 | — |